Table 3.

Clinical trials of HDAC inhibitors in combination with other anticancer agents.

HDACIs	Combination Drugs	Clinical Trial Phase	Clinical Trial ID	Cancer Type	Trial Description	Status	References
Vorinostat (SAHA)	Paclitaxel, Trastuzumab, Doxorubicin, Cyclo-phosphamide	I and II	NCT00574587	Breast cancer, gastric cancer	To determine the optimal dose of vorinostat when combined with standard chemotherapy alone (or with trastuzumab when treating HER2-positive cancer).	Completed	[160]
	Doxorubicin hydrochloride	I	NCT00331955	Unspecified adult solid tumor	Vorinostat may help doxorubicin work better by making tumor cells more sensitive to the drug.	Completed	[161]
	Capecitabine and cisplatin	I and II	NCT01045538	Non-small cell lung	Phase 1—maximum tolerated dose, Phase 2—response rate.	Completed	[162]
	Bortezomib	II	NCT00798720	Cancer	The combination showed a weak anti-tumor activity as third-line therapy in NSCLC.	Completed	[163]
Panobinostat (LBH589)	Trastuzumab/ Paclitaxel	I	NCT00788931	HER-2-positive breast cancer, metastatic breast cancer	Combination is well tolerated.	Completed	[164]
	Capecitabine Lapatinib	I	NCT00632489	Lung vancer, head and neck cancer	Combination of Panobinostat and capecitabine is well tolerated at the recommended doses.	Completed	[165]
	Erlotinib	I	NCT00738751	Lung adenocarcinoma	Panobinostat increases the sensitivity of lung adenocarcinoma cells to the antiproliferative effects of erlotinib. (synergism)	Completed	[166]
Belinostat (PXD101)	Doxorubicin	I/II	NCT00878800	Solid tumors and soft tissue sarcomas	No evidence of synergy between belinostat and doxorubicin in terms of objective tumour shrinkage.	Completed	[167]
Valproic Acid	Epirubicin 5-Fluorouracil Cyclo-phosphamide	I	NCT00246103	Advanced neoplasms	Maximum tolerated dose and recommended phase II dose was VPA 140 mg/kg/d for 48 h followed by epirubicin 100 mg/m2.	Completed	[156]